What is William Blair’s Estimate for DGX FY2025 Earnings?

Quest Diagnostics Incorporated (NYSE:DGX) – Analysts at William Blair lifted their FY2025 earnings per share estimates for Quest Diagnostics in a report issued on Tuesday, October 21st. William Blair analyst A. Brackmann now forecasts that the medical research company will earn $9.73 per share for the year, up from their previous forecast of $9.67. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Quest Diagnostics’ current full-year earnings is $9.70 per share. William Blair also issued estimates for Quest Diagnostics’ Q4 2025 earnings at $2.43 EPS, Q1 2026 earnings at $2.38 EPS, Q2 2026 earnings at $2.66 EPS, Q3 2026 earnings at $2.58 EPS, Q4 2026 earnings at $2.57 EPS and FY2026 earnings at $10.20 EPS.

Quest Diagnostics (NYSE:DGX) last released its earnings results on Tuesday, October 21st. The medical research company reported $2.60 earnings per share for the quarter, beating the consensus estimate of $2.51 by $0.09. Quest Diagnostics had a return on equity of 15.24% and a net margin of 9.01%.The firm had revenue of $2.82 billion for the quarter, compared to analyst estimates of $2.73 billion. During the same quarter in the prior year, the firm posted $2.30 earnings per share. The company’s quarterly revenue was up 13.2% on a year-over-year basis. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS.

DGX has been the topic of several other research reports. Baird R W lowered Quest Diagnostics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 25th. Barclays increased their target price on Quest Diagnostics from $185.00 to $190.00 and gave the company an “equal weight” rating in a research note on Thursday, October 2nd. UBS Group increased their target price on Quest Diagnostics from $180.00 to $190.00 and gave the company a “neutral” rating in a research note on Friday. Jefferies Financial Group increased their target price on Quest Diagnostics from $200.00 to $215.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Robert W. Baird restated a “neutral” rating and issued a $194.00 price target on shares of Quest Diagnostics in a report on Monday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $193.19.

Quest Diagnostics Trading Down 3.1%

NYSE:DGX opened at $184.48 on Wednesday. Quest Diagnostics has a 1-year low of $148.70 and a 1-year high of $197.55. The business’s 50-day moving average price is $182.80 and its two-hundred day moving average price is $176.46. The company has a current ratio of 1.09, a quick ratio of 0.99 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $20.63 billion, a price-to-earnings ratio of 22.09, a PEG ratio of 2.53 and a beta of 0.56.

Quest Diagnostics Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, October 20th. Shareholders of record on Friday, October 3rd were issued a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 1.7%. The ex-dividend date was Friday, October 3rd. Quest Diagnostics’s dividend payout ratio is 38.32%.

Insiders Place Their Bets

In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 227 shares of the stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $188.13, for a total value of $42,705.51. Following the completion of the sale, the senior vice president directly owned 38,117 shares in the company, valued at $7,170,951.21. This represents a 0.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Karthik Kuppusamy sold 2,210 shares of the company’s stock in a transaction dated Thursday, July 31st. The stock was sold at an average price of $170.00, for a total value of $375,700.00. Following the transaction, the senior vice president directly owned 8,450 shares of the company’s stock, valued at $1,436,500. This represents a 20.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 53,186 shares of company stock worth $9,647,471 over the last ninety days. 8.16% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Pinnacle Bancorp Inc. boosted its position in shares of Quest Diagnostics by 126.9% during the second quarter. Pinnacle Bancorp Inc. now owns 152 shares of the medical research company’s stock worth $27,000 after buying an additional 85 shares during the period. True Wealth Design LLC boosted its position in shares of Quest Diagnostics by 369.7% during the third quarter. True Wealth Design LLC now owns 155 shares of the medical research company’s stock worth $30,000 after buying an additional 122 shares during the period. MTM Investment Management LLC acquired a new position in shares of Quest Diagnostics during the second quarter worth about $29,000. AlphaQuest LLC boosted its position in shares of Quest Diagnostics by 18,400.0% during the second quarter. AlphaQuest LLC now owns 185 shares of the medical research company’s stock worth $33,000 after buying an additional 184 shares during the period. Finally, First Horizon Advisors Inc. boosted its position in shares of Quest Diagnostics by 76.6% during the first quarter. First Horizon Advisors Inc. now owns 189 shares of the medical research company’s stock worth $32,000 after buying an additional 82 shares during the period. 88.06% of the stock is owned by institutional investors and hedge funds.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.